NCT06475846View on ClinicalTrials.gov

A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

October 29, 2024

Study Completion Date

October 29, 2024

Conditions
Preventing of Postoperative Nausea and Vomiting in Adults
Interventions
DRUG

HRS5580

HRS5580; low dose

DRUG

HRS5580

HRS5580; middle dose

DRUG

HRS5580

HRS5580; middle dose

DRUG

Ondansetron

Ondansetron

DRUG

blank preparation

blank preparation.

Trial Locations (2)

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

410013

Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06475846 - A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults | Biotech Hunter | Biotech Hunter